Irritable Bowel Syndrome

Gastroenterology
18
Pipeline Programs
18
Companies
11
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
14
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 21 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Plus Therapeutics
2 programs
1
1
Skal ProPhase 41 trial
L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®Phase 21 trial
Active Trials
NCT01545037CompletedEst. Jan 2015
NCT06271538RecruitingEst. Nov 2025
Sanofi
SanofiPARIS, France
1 program
1
Bacillus clausiiPhase 41 trial
Active Trials
NCT00331994Completed250Est. Jul 2008
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
5 programs
4
1
PlecanatidePhase 3Peptide1 trial
RifaximinPhase 21 trial
RifaximinPhase 21 trial
crofelemerPhase 21 trial
crofelemerPhase 21 trial
Active Trials
NCT00269412CompletedEst. Sep 2008
NCT00259155CompletedEst. Jan 2007
NCT00461526CompletedEst. Dec 2007
+2 more trials
Astellas
AstellasChina - Shenyang
3 programs
2
1
YM060Phase 32 trials
YM060Phase 21 trial
YM060Phase 21 trial
Active Trials
NCT01274000Completed409Est. Oct 2011
NCT00189813Completed691Est. Dec 2005
NCT00189696Completed
+1 more trials
Pfizer
PfizerNEW YORK, NY
2 programs
2
PD-217,014Phase 21 trial
Rimegepant 75 MG [Nurtec]Phase 21 trial
Active Trials
NCT00139672Completed330Est. Feb 2005
NCT06221111Completed24Est. Jun 2025
Novartis
NovartisBASEL, Switzerland
1 program
1
DNK333Phase 21 trial
Active Trials
NCT00699166Completed135Est. Sep 2005
Seed Therapeutics
Seed TherapeuticsNY - New York
1 program
1
DS-01Phase 21 trial
Active Trials
NCT04598295CompletedEst. Oct 2022
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
EluxadolinePhase 22 trials
Active Trials
NCT04880876Enrolling By Invitation124Est. Dec 2032
NCT03339128Recruiting95Est. Dec 2026
Ironwood Pharmaceuticals
1 program
1
MD-1100 AcetatePhase 21 trial
Active Trials
NCT00258193CompletedEst. Sep 2006
Tillotts Pharma
Tillotts PharmaSwitzerland - Rheinfelden
1 program
1
MesalazinePhase 21 trial
Active Trials
NCT01699438CompletedEst. Feb 2017
Cook Medical
Cook MedicalIN - Bloomington
1 program
Confocal Laser EndomicroscopyN/A
Meliora Therapeutics
Meliora TherapeuticsCA - San Francisco
1 program
Confocal Laser EndomicroscopyN/A1 trial
Active Trials
NCT06792838Not Yet RecruitingEst. Sep 2034
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Gastrointestinal Permeability TestN/A1 trial
Active Trials
NCT02358564Completed39Est. Mar 2021
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Low- FODMAPdiet group interventionN/A1 trial
Active Trials
NCT05124262Not Yet RecruitingEst. Mar 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Plus TherapeuticsSkal Pro
SanofiBacillus clausii
AbbVieEluxadoline
Bausch HealthPlecanatide
PfizerRimegepant 75 MG [Nurtec]
Seed TherapeuticsDS-01
AbbVieEluxadoline
Plus TherapeuticsL. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
Tillotts PharmaMesalazine
AstellasYM060

Clinical Trials (11)

Total enrollment: 902 patients across 11 trials

NCT06271538Plus TherapeuticsSkal Pro

Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome

Start: Oct 2024Est. completion: Nov 2025
Phase 4Recruiting
NCT00331994SanofiBacillus clausii

EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth

Start: Apr 2006Est. completion: Jul 2008250 patients
Phase 4Completed
NCT00189696AstellasYM060

Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Phase 3Completed
NCT04880876AbbVieEluxadoline

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Start: Aug 2021Est. completion: Dec 2032124 patients
Phase 3Enrolling By Invitation
NCT02706483Bausch HealthPlecanatide

Long Term Safety Study of Plecanatide

Start: Jan 2016Est. completion: Jun 2017
Phase 3Completed
NCT06221111PfizerRimegepant 75 MG [Nurtec]

Comparison of Rimegepant and Placebo for Pain in IBS

Start: Jun 2024Est. completion: Jun 202524 patients
Phase 2Completed
NCT04598295Seed TherapeuticsDS-01

SH-DS01 on Fecal Metagenomic Stability

Start: Oct 2020Est. completion: Oct 2022
Phase 2Completed
NCT03339128AbbVieEluxadoline

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

Start: Nov 2017Est. completion: Dec 202695 patients
Phase 2Recruiting
NCT01545037Plus TherapeuticsL. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®

Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome

Start: Jul 2012Est. completion: Jan 2015
Phase 2Completed
NCT01699438Tillotts PharmaMesalazine

Mesalazine Treatment in IBS (The MIBS Study)

Start: Apr 2012Est. completion: Feb 2017
Phase 2Completed
NCT01274000AstellasYM060

A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients

Start: Nov 2010Est. completion: Oct 2011409 patients
Phase 2Completed

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
7h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 902 patients
18 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)Gastrointestinal Tolerance(12)